About Index Trending news
Analyze
Pricing
Alimera Sciences

Alimera Sciences

Work at Alimera Sciences? Add yourself to this profile

Alimera Sciences

Biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals with a focus on the back of the eye, or retina.
Edit Profile
More info

Elsewhere

Companies in the same industry

Clontech Laboratories Inc Clontech Laboratories Inc Prospective Research Prospective Research Napo Pharmaceuticals Napo Pharmaceuticals Esperion Therapeutics Esperion Therapeutics XOR Labs Toronto XOR Labs Toronto Prexton Therapeutics SA Prexton Therapeutics SA Mycodev Group Mycodev Group AFFiRiS AG AFFiRiS AG Promentis Pharmaceuticals Promentis Pharmaceuticals Perlecan Pharma Perlecan Pharma

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 2
Add info
Latest funding
Post-IPO equity
$26,500,000
Post-IPO debt
$35,000,000
Employees

Team size

50+
Locations
HQ
United States
Headquarters
$26,500,000 Post-IPO equity
GlobeNewswire News Room

Alimera Sciences Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $26.5 Million Offering of Common Stock

Alimera Sciences
Alimera Sciences